+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-01-24Number of Pages: 124

Short Bowel Syndrome Market (Drug Class - GLP-2, Growth Hormone, and Glutamine) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Global Short Bowel Syndrome Market: Snapshot

Short bowel syndrome (SBS) refers to a disorder that occurs due to the malfunction of the intestine, leading to malabsorption. SBS can be an outcome of various underlying diseases or medical conditions that can cause resection of the intestine. Owing to this the nutrient processing areas in the intestine rendered dysfunction and can lead to dangerous infectious and metabolic disorders. The research report predicts that the global short bowel syndrome market is expected to rise at a CAGR of 30.4% to reach a valuation of US$2.6 bn by the end of 2024 as compared to be US$312.7 mn in 2016.

The disease can be congenital or can be a result of underlying diseases such as Crohn’s disease, intestinal failure, tumors, injury or trauma to the small intestine. Necrotizing enterocholitis is observed to be the cause of short bowel syndrome amongst neonates and infants. The research report estimates that the postoperative complications arising out of vascular and obstructive anomalies, which need extensive resection have been on the rise. These complications have also been making a significant contribution to high prevalence SBS across the globe.

short bowel syndrome market

GLP-2 Emerges as Popular Drug Class due to Approvals in North America and Europe

On the basis of drugs, the global short bowel syndrome market is segmented into GLP-2, growth hormone, glutamine, and others. Presently, GLP-2 is leading the global market due to its wide presence in the U.S. and Europe. The GLP-2 drug, composed of teduglutide as the primary ingredient, is sold under the brand name of Gattex in the U.S. and as Revestive in Europe and other international markets. The other drugs available for SBS in the U.S. market are Zorbtive (growth hormone) and NutreStore (Glutamine). However, Revestive is the sole drug designed for specifically treating SBS. Owing to the specificity of these drugs and their wide availability in the regions, these drugs are expected to make significant contributions to the rising revenue of the global market during the forecast period. The drugs currently have an orphan drug status and thus enjoy drug exclusivity that has a growing pool of patients. Presently, this drug has also reached phase III of clinical trials in Japan, which could open up several lucrative opportunities to treat adults as well as infants.

North America Retains Lead due to Increasing Prescriptions for Gattex Therapy

In terms of geography, the global short bowel syndrome market is fragmented into North America, Europe, and Rest of the World. Of these, North America is expected to dominate the global market in the coming years. The increasing prescriptions for Gattex therapy in the U.S. is expected to be the key growth driver for the North America short bowel syndrome market. Furthermore, the fact that glutamine and growth hormone are only approved in the U.S. for treating SBS is expected to keep North America in the lead. The growing awareness about short bowel syndrome amongst consumers and excellent reimbursement strategies are expected to drive the regional market in the coming years.

The key players operating in the global short bowel syndrome market are Shire plc, Merck KGaA, and Emmaus Life Sciences, Inc. As of 2015, Shire held a whopping share of 50% in the overall market with its blockbuster drugs, making the competitive landscape fairly competitive. The other important players operating in the global market are Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc., Sancilio & Company, Inc., Naia Pharmaceuticals, and Zealand Pharma A/S.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Short Bowel Syndrome

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Class Definition
            4.1.2. Industry Evolution / Developments
     4.2. Market Dynamics
            4.2.1. Drivers
            4.2.2. Restraints
            4.2.3. Opportunity     
     4.3. Global Short Bowel Syndrome Analysis and Forecasts, 2014–2024
            4.3.3. Market Revenue Projections (US$ Mn)
     4.4. Porter’s Five Force Analysis
     4.5. Value Chain Analysis
     4.6. Market Outlook
     4.7. Disease Overview
     4.8. Disease Epidemiology
     4.9. Patent Information
     4.10. Overview of Clinical Trials
     4.11. Qualitative Analysis of GLP-2 product
     4.12. Mode of action of SBS drugs
     4.13. Regulatory Scenario

5. Global Short Bowel Syndrome Analysis and Forecasts, By Drug Class 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends     
     5.4. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
            5.4.1. GLP-2 
            5.4.2. Growth Hormone
            5.4.3. Glutamine
            5.4.4. Others
     5.5. Market Attractiveness by Drug Class 

6. Global Short Bowel Syndrome Analysis and Forecasts, By Region
     6.1. Key Findings
     6.2. Market Value (US$ Mn) Forecast By Region
            6.2.1. North America  
            6.2.2. Europe 
            6.2.3. Rest of the World 
     6.3. Market Attractiveness by Country/Region

7. North America Short Bowel Syndrome Analysis and Forecast
     7.1. Introduction
            7.1.1. Key Findings
            7.1.2. Key Trends
     7.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
            7.2.1. GLP-2 
            7.2.2. Growth Hormone
            7.2.3. Glutamine
            7.2.4. Others
     7.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
            7.3.1. U.S. 
            7.3.2. Canada
     7.3. Market Attractiveness Analysis 
            7.3.1. By Drug Class 
            7.3.2. By Country

8. Europe Short Bowel Syndrome Analysis and Forecast
     8.1. Introduction
            8.1.1. Key Findings
            8.1.2. Key Trends
     8.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
            8.2.1. GLP-2 
            8.2.2. Growth Hormone
            8.2.3. Glutamine
            8.2.4. Others
     8.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
            8.3.1. U.K.
            8.3.2. Germany
            8.3.3. France
            8.3.4. Italy
            8.3.5. Spain
            8.3.6. Rest of Europe
     8.4. Market Attractiveness Analysis 
            8.4.1. By Drug Class 
            8.4.2. By Country

9. Rest of the World Short Bowel Syndrome Analysis and Forecast
     9.1. Introduction
     9.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
     9.3. Regional Insights
            9.3.1. Japan
            9.3.2. India
            9.3.3. Australia/New Zealand
            9.3.4. China
            9.3.5. Middle East
            9.3.6. Brazil

10. Competition Landscape
     10.1. Market Player – Competition Matrix (By Tier and Size of companies)
     10.2. Market Share Analysis by Company (2015)
     10.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            10.3.1. Ardelyx, Inc.
                      10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.1.2. Business Overview
                      10.3.1.3. Product Portfolio 
                      10.3.1.4. Financial Overview 
                      10.3.1.5. SWOT Analysis 
                      10.3.1.6. Strategic overview
            10.3.2. Emmaus Life Sciences, Inc.
                      10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.2.2. Business Overview
                      10.3.2.3. Product Portfolio 
                      10.3.2.4. Financial Overview 
                      10.3.2.5. SWOT Analysis 
                      10.3.2.6. Strategic overview
            10.3.3. GLyPharma Therapeutic, Inc.
                      10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.3.2. Business Overview
                      10.3.3.3. Product Portfolio 
                      10.3.3.4. Financial Overview 
                      10.3.3.5. SWOT Analysis 
                      10.3.3.6. Strategic overview
            10.3.4. Merck KGaA
                      10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.4.2. Business Overview
                      10.3.4.3. Product Portfolio 
                      10.3.4.4. Financial Overview 
                      10.3.4.5. SWOT Analysis 
                      10.3.4.6. Strategic overview
            10.3.5. Naia Pharmaceuticals, Inc.
                      10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.5.2. Business Overview
                      10.3.5.3. Product Portfolio 
                      10.3.5.4. Financial Overview 
                      10.3.5.5. SWOT Analysis 
                      10.3.5.6. Strategic overview
            10.3.6. Nutrinia Ltd.
                      10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.6.2. Business Overview
                      10.3.6.3. Product Portfolio 
                      10.3.6.4. Financial Overview 
                      10.3.6.5. SWOT Analysis 
                      10.3.6.6. Strategic overview
            10.3.7. OxThera
                      10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.7.2. Business Overview
                      10.3.7.3. Product Portfolio 
                      10.3.7.4. Financial Overview 
                      10.3.7.5. SWOT Analysis 
                      10.3.7.6. Strategic overview
            10.3.8. Sancilio & Company, Inc.
                      10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.8.2. Business Overview
                      10.3.8.3. Product Portfolio 
                      10.3.8.4. Financial Overview 
                      10.3.8.5. SWOT Analysis 
                      10.3.8.6. Strategic overview
            10.3.9. Shire plc
                      10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.9.2. Business Overview
                      10.3.9.3. Product Portfolio 
                      10.3.9.4. Financial Overview 
                      10.3.9.5. SWOT Analysis 
                      10.3.9.6. Strategic overview
            10.3.10. Zealand Pharma A/S
                      10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                      10.3.10.2. Business Overview
                      10.3.10.3. Product Portfolio 
                      10.3.10.4. Financial Overview 
                      10.3.10.5. SWOT Analysis 
                      10.3.10.6. Strategic overview

List of Figures

Figure 01: Global Short Bowel Syndrome Size (US$ Mn) and Forecast, 2016–2024
Figure 02: Global Market Value Share, by Drug Class (2016)
Figure 03: Global Market Value Share, by Region (2016)
Figure 04: Causes of SBS in neonates in neonatal intensive care units (NICU)
Figure 05: Causes of SBS in adults
Figure 06: Global Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and
Figure 07: Global GLP-2 Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 08: Global Growth Hormone Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Glutamine Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class
Figure 12: Global Short Bowel Syndrome Market Revenue, US$ Mn, 2014–2024
Figure 13: Global Short Bowel Syndrome Market Value Share Analysis, by Region, 2015 and 2024
Figure 14: Short Bowel Syndrome Market Attractiveness Analysis, by Region
Figure 15: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 16: North America Market Attractiveness Analysis, by Drug Class
Figure 17: North America Market Attractiveness Analysis, by Country
Figure 18: North America Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 19: North America Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024 
Figure 20: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 21: Europe Market Attractiveness Analysis, by Drug Class
Figure 22: Europe Market Attractiveness Analysis, by Country
Figure 23: Europe Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 24: Europe Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024
Figure 25: Rest of the World Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 26: Global Short Bowel Syndrome Market Share Analysis, by Company (2015)

List of Tables

Table 01: Overview of clinical trials for short bowel syndrome
Table 02: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 03: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 04: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 05: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 07: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024    

Global Short Bowel Syndrome Market: Overview

Short bowel syndrome (SBS) is an intestinal disorder associated with malabsorption due to the lack of functional intestine. SBS can be congenital or an acquired condition which can be observed in patients in whom nearly half of the small intestine has been removed due to underlying disease condition. In certain instances, a major part of the large intestine is removed through surgeries that might result in SBS in the patients. The major causes of SBS in infants include necrotizing enterocolitis, intestinal atresia, gastroschisis, and malrotation with volvulus, among others. In adults, SBS is observed in Crohn’s disease, radiation enteritis, and mesenteric ischemia, among others. The medications prescribed for the treatment of SBS include teduglutide and growth hormones (aid in intestinal absorption), proton pump inhibitors (used to treat gastric acid secretions), and anti-diarrheal (to treat the primary symptom of SBS, i.e., diarrhea). As the patients with SBS have lost major part of the intestine, retaining nutrients in such patients through oral nutrition becomes difficult. Hence parenteral nutrition is the preferred mode of treatment in these patients. 

Global Short Bowel Syndrome Market: Research Methodologies

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of drugs employed in the treatment of short bowel syndrome in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for drug class, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each drug class was calculated by considering prevalence rate of short bowel syndrome, the cost of the drugs, reimbursement scenario, drug availability, patent expiries, and adoption rate of the drugs, across all the geographies.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the short bowel syndrome market in the current and future scenario. The report also provides value chain analysis of the market that describes the sequence of activities involved, from identification of the market need to their final reach to the end users.

Global Short Bowel Syndrome Market: Scope of the Study

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, and Rest of the World. The study also covers detailed country analysis contributing majorly in the short bowel syndrome market.

Key Players Mentioned in this Report are:

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the short bowel syndrome market report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, and Zealand Pharma A/S, among others.

The Short Bowel Syndrome Market has been segmented as follows:

  • Short Bowel Syndrome Market, by Drug Class, Revenue (US$ Mn) 2014-2024
    • GLP-2
    • Growth Hormone
    • Glutamine
    • Others
  • Short Bowel Syndrome Market Revenue, by Geography (US$ Mn), 2014-2024
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Spain
      • France
      • Italy
      • Rest of Europe
    • Rest of the World


 
 
Back To Top